In short
Clinical trials are studying MEASLES VIRUS EDMONSTON-SCHWARZ STRAIN (LIVE, ATTENUATED) PRODUCED IN CHICK EMBRYO CELLS in children and adolescents. These studies look at immune response, safety, and how well measles-containing vaccines work in different groups, including healthy toddlers and children after cancer treatment.
Key points
- Clinical trials of MEASLES VIRUS EDMONSTON-SCHWARZ STRAIN (LIVE, ATTENUATED) PRODUCED IN CHICK EMBRYO CELLS are studying measles-containing vaccination in two main groups: children and adolescents after childhood cancer treatment, and healthy children 12 to 15 months old. Both studies are Phase 3 and are authorised. The main goals are to measure immune response and protection, using antibody levels and seroresponse as endpoints. One trial looks at revaccination after cancer therapy for measles and chickenpox protection. The other trial compares intramuscular and subcutaneous vaccination methods for varicella and MMR vaccines. Together, the trials focus on how well these vaccines work in real patient groups.
Trial overview
Two authorised Phase 3 clinical trials are studying MEASLES VIRUS EDMONSTON-SCHWARZ STRAIN (LIVE, ATTENUATED) PRODUCED IN CHICK EMBRYO CELLS in different patient groups. One trial focuses on children and adolescents after childhood cancer treatment, and the other focuses on healthy children 12 to 15 months old.
These studies are not testing the substance as a stand-alone treatment. They are looking at vaccine response, protection, and safety in real-life groups who need measles-containing vaccination or varicella vaccination.
Study populations and conditions
The first trial includes children and adolescents from 0 to 18 years old with pediatric cancer. Its main goal is to examine immunity after revaccination against measles and chickenpox after treatment for childhood cancer.
The second trial includes healthy children 12 to 15 months of age and studies varicella, which is the medical name for chickenpox. This study also includes a marketed measles, mumps and rubella vaccine and compares different ways of giving the vaccines.
In the trial summaries, the vaccine names include MEASLES, COMBINATIONS WITH MUMPS AND RUBELLA, LIVE ATTENUATED and VARICELLA, LIVE ATTENUATED, along with a study vaccine listed as GSKVX000000025896.
Main outcomes and endpoints
The first trial measures the difference in VZ IgG antibody levels before and after revaccination against chickenpox, and the difference in measles IgG antibody levels before and after revaccination against measles. In simple terms, it checks whether antibody protection improves after the vaccines are given again.
The trial summary also states that the researchers will look at the proportion of patients with a protective VZ-IgG level after vaccination compared with before vaccination, and the proportion with a protective morbilli-IgG level after vaccination compared with before vaccination. Morbilli is another name used for measles in the study text.
The second trial measures seroresponse to VZV gE and to MMR antigens at Day 43, plus anti-VZV gE IgG concentration and anti-measles, anti-mumps, and anti-rubella IgG concentrations at Day 43. These are blood test measures that show whether the immune system responded after vaccination.
This second study has a non-inferiority goal, which means it is checking whether intramuscular vaccination is not worse than subcutaneous vaccination by more than an allowed amount. It compares intramuscular administration with subcutaneous administration for both the varicella vaccine and the MMR vaccine.
Trial design, phase, and status
Both studies are interventional, which means researchers actively give the vaccine and then measure the results. Both are also marked Authorised in the source data.
The first trial has an enrollment of 160 participants. The second trial has a larger enrollment of 944 participants. Larger enrollment can help researchers compare immune responses more reliably across groups.
The first trial is focused on revaccination after childhood cancer treatment, while the second trial is focused on vaccination in young healthy children and on comparing injection routes. Together, they show how the same vaccine-related research topic can be studied in different populations and for different practical questions.
What the study results mean for patients
For families, the key question in these trials is whether vaccination leads to enough antibody protection after cancer treatment or in early childhood. The studies use blood tests to see if the immune system has responded in a measurable way.
The first study is especially relevant for children and teenagers who may need protection again after cancer therapy. The second study is especially relevant for healthy toddlers who are receiving routine vaccine protection and for understanding whether two injection methods give similar immune results.
Overall, the trial data focus on immune response, protection levels, age group, and how the vaccine is given, rather than on long-term disease outcomes.